title: Does therapy with anti-TNF-alpha improve glucose tolerance and control in patients with type 2 diabetes?
authors.forename: Malini
authors.initials: M
authors.lastname: Gupta-Ganguli
authors.forename: Kyle
authors.initials: K
authors.lastname: Cox
authors.forename: Blake
authors.initials: B
authors.lastname: Means
authors.forename: Ivan
authors.initials: I
authors.lastname: Gerling
authors.forename: Solomon S
authors.initials: SS
authors.lastname: Solomon
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001786:Blood Glucose; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D001786:Blood Glucose; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept